Source: Health Canada shortage reports · Updated Oct 1, 2026
Raltitrexed is in a widespread shortage in Canada. 1 of 1 reported products are affected, and Health Canada has designated this a Tier 3 (most serious) shortage. The latest manufacturer estimate for full recovery is Dec 31, 2028.
Products affected
1 / 1
In shortage since
Aug 7, 2026
Est. full return
Dec 31, 2028
Reports on file
7
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
TOMUDEX
2MG · POWDER FOR SOLUTION · PFIZER CANADA ULC
DIN 02229566 · since Aug 7, 2026, est. end Dec 31, 2028 · Disruption of the manufacture of the drug.
Resolved
TOMUDEX
2MG · POWDER FOR SOLUTION · PFIZER CANADA ULC
DIN 02229566 · ended Sep 3, 2024 · Disruption of the manufacture of the drug.
Resolved
TOMUDEX
2MG · POWDER FOR SOLUTION · PFIZER CANADA ULC
DIN 02229566 · ended Jan 31, 2024 · Disruption of the manufacture of the drug.
Resolved
TOMUDEX
2MG · POWDER FOR SOLUTION · PFIZER CANADA ULC
DIN 02229566 · ended Jan 10, 2020 · Disruption of the manufacture of the drug.
Resolved
TOMUDEX
2MG · POWDER FOR SOLUTION · PFIZER CANADA ULC
DIN 02229566 · ended Sep 30, 2019 · Disruption of the manufacture of the drug.
Resolved
TOMUDEX
2MG · POWDER FOR SOLUTION · PFIZER CANADA INC
DIN 02229566 · ended Oct 12, 2018 · Disruption of the manufacture of the drug.
Resolved
TOMUDEX
2MG · SOLUTION · HOSPIRA HEALTHCARE CORPORATION
DIN 02229566 · ended May 25, 2017 · Disruption of the manufacture of the drug.
What's happening
Raltitrexed is currently affected by an active shortage report filed with Health Canada by PFIZER CANADA ULC.
The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
Health Canada has flagged this as a Tier 3 shortage, its most serious category, meaning the shortage has the greatest potential impact on the health system and alternatives are limited.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Raltitrexed is classified under “ANTIMETABOLITES” (ATC L01BA).
Recent changes
Oct 1, 2026
Status changed
Oct 1, 2026
Estimated end date pushed back : Mar 31, 2027 → Dec 31, 2028
Aug 31, 2026
Tier 3 designation changed
Aug 7, 2026
New report filed
Common questions
When will Raltitrexed be back in stock in Canada?
The latest manufacturer estimate is Dec 31, 2028. Estimates are self-reported and often slip; this page updates automatically when they change.
Why is Raltitrexed in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.